EVGN
Evogene Ltd
$
1.150
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.200
Open
1.170
VWAP
1.15
Vol
30.20K
Mkt Cap
10.02M
Low
1.120
Amount
34.68K
EV/EBITDA(TTM)
--
Total Shares
50.66M
EV
27.03M
EV/OCF(TTM)
--
P/S(TTM)
0.83
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
3.00M
+22.75%
-0.320
-15.79%
1.83M
+13.28%
-0.345
-675%
575.00K
-67.98%
-0.425
-67.56%
Estimates Revision
The market is revising Downward the revenue expectations for Evogene Ltd. (EVGN) for FY2025, with the revenue forecasts being adjusted by -32.22% over the past three months. During the same period, the stock price has changed by -4.96%.
Revenue Estimates for FY2025
Revise Downward
-32.22%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+27.22%
In Past 3 Month
Stock Price
Go Down
-4.96%
In Past 3 Month
1 Analyst Rating
Wall Street analysts forecast EVGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVGN is 3.50 USD with a low forecast of 3.50 USD and a high forecast of 3.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.150
Low
3.50
Averages
3.50
High
3.50
Current: 1.150
Low
3.50
Averages
3.50
High
3.50
Alliance Global Partners
Scott Henry
Buy
downgrade
$6
2025-06-06
Reason
Alliance Global Partners
Scott Henry
Price Target
$6
2025-06-06
downgrade
Buy
Reason
Alliance Global Partners analyst Scott Henry lowered the firm's price target on Evogene to $3.50 from $6 and keeps a Buy rating on the shares, citing lower forecasts and potentially higher equity dilution after the company reported Q1 earnings that featured a revenue shortfall offset by cost cuts. The Lavie Bio sale should fortify the balance sheet, although at a lower price than expected, and Casterra castor seed revenue continues to trail the firm's forecasts, the analyst noted.
Lake Street
Ben Klieve
Buy
downgrade
$5
2025-05-22
Reason
Lake Street
Ben Klieve
Price Target
$5
2025-05-22
downgrade
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Evogene Ltd (EVGN.O) is -0.71, compared to its 5-year average forward P/E of -2.15. For a more detailed relative valuation and DCF analysis to assess Evogene Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.15
Current PE
-0.71
Overvalued PE
-0.07
Undervalued PE
-4.23
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.50
Current EV/EBITDA
-1.90
Overvalued EV/EBITDA
0.25
Undervalued EV/EBITDA
-1.26
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
48.61
Current PS
1.16
Overvalued PS
146.46
Undervalued PS
-49.23
Financials
Annual
Quarterly
FY2025Q2
YoY :
-141.30%
783.00K
Total Revenue
FY2025Q2
YoY :
-62.88%
-1.97M
Operating Profit
FY2025Q2
YoY :
-53.06%
-2.44M
Net Income after Tax
FY2025Q2
YoY :
-41.51%
-0.62
EPS - Diluted
FY2025Q2
YoY :
-87.48%
-687.00K
Free Cash Flow
FY2025Q2
YoY :
+32.27%
95.02
Gross Profit Margin - %
FY2025Q2
YoY :
-42.53%
-175.56
FCF Margin - %
FY2025Q2
YoY :
-20.90%
-312.13
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
EVGN News & Events
Events Timeline
2025-08-22 (ET)
2025-08-22
05:52:22
Evogene announces Q2 earnings per share of 10 cents, compared to a loss of 5 cents last year.
2025-08-19 (ET)
2025-08-19
07:06:04
Evogene announces Q2 continuing operations EPS of 50 cents compared to a loss of 85 cents last year.
2025-06-10 (ET)
2025-06-10
07:11:52
Evogene announces completion of generative AI foundation model with Google Cloud
Sign Up For More Events
Sign Up For More Events
News
9.5
11-06PRnewswirePinnedEvogene Schedules Third Quarter 2025 Financial Results Release
4.5
09-26NewsfilterEverGen Infrastructure Shares Updates on Operations and Development
1.0
08-28PRnewswireEvogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York
Sign Up For More News
People Also Watch
EONR
EON Resources Inc
0.485
USD
-4.34%
INTJ
Intelligent Group Ltd
0.548
USD
-0.18%
SOGP
Sound Group Inc
12.850
USD
-2.50%
CJET
Chijet Motor Co Inc
2.500
USD
-13.19%
PMAX
Powell Max Ltd
2.160
USD
-0.92%
VRAX
Virax Biolabs Group Ltd
0.481
USD
-3.80%
CREV
Carbon Revolution PLC
4.000
USD
-1.72%
ASNS
Actelis Networks Inc
0.441
USD
+6.26%
KLTO
Klotho Neurosciences Inc
0.468
USD
-3.10%
FAQ
What is Evogene Ltd (EVGN) stock price today?
The current price of EVGN is 1.15 USD — it has decreased -0.86 % in the last trading day.
What is Evogene Ltd (EVGN)'s business?
What is the price predicton of EVGN Stock?
What is Evogene Ltd (EVGN)'s revenue for the last quarter?
What is Evogene Ltd (EVGN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Evogene Ltd (EVGN)'s fundamentals?
How many employees does Evogene Ltd (EVGN). have?